专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20170172120A1 PREVENTIVE OR THERAPEUTIC AGENT FOR KIDNEY DISEASE 审中-公开
公开(公告)号：US20170172120A1
公开(公告)日：2017-06-22
申请号：US15116907
申请日：2015-02-06
申请人： MIYAZAKI, Toru
发明人： Toru MIYAZAKI
IPC分类号： A01K67/027 , A61K45/06 , G01N33/68 , A61K38/17
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/035 , A61K31/7088 , A61K38/00 , A61K38/1761 , A61K45/06 , C07K14/435 , G01N33/6893 , G01N2333/775 , G01N2800/347 , G01N2800/52
摘要： The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising AIM or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia/reperfusion and the like.

72. 发明申请

US20170138968A1 ApoIII and the Treatment and Diagnosis of Diabetes 审中-公开
公开(公告)号：US20170138968A1
公开(公告)日：2017-05-18
申请号：US15409027
申请日：2017-01-18
申请人： BioCrine AB
发明人： Per-Olof BERGGREN
IPC分类号： G01N33/92 , C07K16/18 , G01N33/50
CPC分类号： G01N33/92 , C07K16/18 , C07K2317/76 , C12N15/113 , C12N2310/11 , C12N2310/14 , G01N30/02 , G01N33/5041 , G01N33/507 , G01N33/564 , G01N2333/775 , G01N2440/38 , G01N2500/10 , G01N2800/042 , G01N2800/50 , G01N2800/52
摘要： The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells.

73. 发明申请

US20170030927A1 METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
标题翻译：用于诊断和预防肾损伤和肾功能衰竭的方法和组合
公开(公告)号：US20170030927A1
公开(公告)日：2017-02-02
申请号：US15295746
申请日：2016-10-17
申请人： ASTUTE MEDICAL, INC.
发明人： Joseph Anderberg , Jeff Gray , Paul McPherson , Kevin Nakamura
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4704 , G01N2333/4709 , G01N2333/475 , G01N2333/4753 , G01N2333/5434 , G01N2333/5446 , G01N2333/55 , G01N2333/57 , G01N2333/775 , G01N2333/96486 , G01N2333/96494 , G01N2800/347 , G16B40/00
摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.
摘要翻译：本发明涉及用于在患有或疑似患有肾损伤的受试者中监测，诊断，预后和确定治疗方案的方法和组合物。特别地，本发明涉及使用检测一种或多种选自Clusterin，心脏型脂肪酸结合蛋白，肝细胞生长因子，干扰素γ，白细胞介素-12亚单位β，白细胞介素-16，白细胞介素-1 2,72kDa IV型胶原酶，基质金属蛋白酶-9，Midkine和血清淀粉样蛋白P组分作为肾损伤的诊断和预后生物标志物。

74. 发明申请

US20170010278A1 METHODS FOR ASSESSING BIOSPECIMEN INTEGRITY 审中-公开
标题翻译：评估BIOSPECIMEN完整性的方法
公开(公告)号：US20170010278A1
公开(公告)日：2017-01-12
申请号：US15119676
申请日：2015-02-11
申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
发明人： Chad Borges , Matthew Schaab , Douglas Rehder
IPC分类号： G01N33/68
CPC分类号： G01N33/6848 , G01N33/49 , G01N2333/76 , G01N2333/775 , G01N2560/00 , Y10T436/24
摘要： Methods for quantifying biospecimen sample integrity using markers of oxidation (FIG. 1). Under conditions of incomplete blood plasma/serum (P IS) sample freezing (including storage at −20 ?C), two different forms of oxidation occur spontaneously at protein sulfur atoms—namely S-cysteinylation of free cysteine residues (in which the oxidative event is disulfide bond formation) and sulfoxidation of methionine. Oxidized forms of albumin and apoA-1, SCA and MOA1 are useful markers of biospecimen integrity. The oxidative chemistries of SCA and MOAI are operational in other proteins and polypeptides. Thus, for rare cases in which the use of SCA or MOA1 may be contraindicated, custom designed surrogate peptide probes based on SCA and MOA1 oxidation chemistry may be fortified into samples at collection to serve as exogenous markers of P/S sample integrity.
摘要翻译：使用氧化标记物定量生物样本样品完整性的方法（图1）。在不完全血浆/血清（P IS）样品冷冻（包括-20℃下保存）的条件下，两种不同形式的氧化在蛋白质硫原子上自发发生，即游离半胱氨酸残基的S-半胱氨酰化（其中氧化事件是二硫键形成）和甲硫氨酸的亚磺氧化。白蛋白和apoA-1，SCA和MOA1的氧化形式是生物样本完整性的有用标记。 SCA和MOAI的氧化化学物质在其他蛋白质和多肽中是可操作的。因此，对于可能禁忌使用SCA或MOA1的罕见情况，可以采集基于SCA和MOA1氧化化学的定制设计的替代肽探针，以收集样品，以充当P / S样品完整性的外源标记。

75. 发明申请

US20160282367A1 METHODS FOR CALIBRATED ION MOBILITY ANALYSIS AND USES THEREOF 审中-公开
标题翻译：用于校准离子电动力分析的方法及其用途
公开(公告)号：US20160282367A1
公开(公告)日：2016-09-29
申请号：US15036901
申请日：2014-11-25
申请人： UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CO MMERCIALIZATION
发明人： Jay HEINECKE , Patrick Moore HUTCHINS
IPC分类号： G01N33/92 , C12Q1/26
CPC分类号： G01N33/92 , C12Q1/26 , G01N33/6893 , G01N2333/775
摘要： The present invention relates to improved ion mobility analysis (IMA) methods that can accurately quantify particle concentration in a sample solution. Specifically, reference particles of known solution-phase concentration are used for calibration. In addition, by exploiting spectral deconvolution techniques, the concentrations of subpopulations within the particles can also be accurately quantified. The improved IMA methods permit, for the first time, the quantification of absolute concentrations of HDL particles and subpopulations thereof in a biological sample. The correlations of HDL particle concentrations and conditions such as LCAT deficiency and cardiovascular diseases have been established. Accordingly, the present invention also provide methods to determine whether a subject is at risk to develop or is suffering from these conditions by using HDL particle concentration as a clinical metric.
摘要翻译：本发明涉及可以准确量化样品溶液中的颗粒浓度的改进的离子迁移率分析（IMA）方法。具体地，使用已知溶液相浓度的参比颗粒进行校准。此外，通过利用光谱去卷积技术，也可以精确量化颗粒内亚群的浓度。改进的IMA方法首次允许定量生物样品中HDL颗粒及其亚群的绝对浓度。已经建立了HDL颗粒浓度与LCAT缺陷和心血管疾病等相关因素。因此，本发明还提供了通过使用HDL颗粒浓度作为临床量度来确定受试者是否处于发展风险或正在遭受这些病症的方法。

76. 发明申请

US20160231332A1 Methods and Devices for Detecting Kidney Damage 审中-公开
标题翻译：检测肾损伤的方法和装置
公开(公告)号：US20160231332A1
公开(公告)日：2016-08-11
申请号：US15014993
申请日：2016-02-03
申请人： Rules-Based Medicine, Inc.
发明人： Samuel T. LaBrie , James P. Mapes , Michael D. Spain , Ralph L. McDade , Dominic P. Eisinger , Karri L. Ballard
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/5302 , G01N33/566 , G01N2333/47 , G01N2333/4703 , G01N2333/4706 , G01N2333/4725 , G01N2333/4727 , G01N2333/475 , G01N2333/52 , G01N2333/70503 , G01N2333/70539 , G01N2333/765 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/82 , G01N2333/91177 , G01N2800/34 , G01N2800/347 , G01N2800/52 , G01N2800/56 , G01N2800/60 , Y10T436/147777
摘要： Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.
摘要翻译：描述了用于诊断，监测或确定哺乳动物肾损伤的方法和装置。具体地说，描述了从哺乳动物取得的测试样品中使用测量浓度的三种或更多种分析物的组合来诊断，监测或确定肾损伤的方法和装置。

77. 发明授权

US09404932B2 Pathology biomarker assay 有权
标题翻译：病理生物标志物检测
公开(公告)号：US09404932B2
公开(公告)日：2016-08-02
申请号：US13187205
申请日：2011-07-20
申请人： Sanne S. Veidal , Morten A. Karsdal , Diana J. Leeming , Natasha Barascuk , Helene Skjøt-Arkil , Efstathios Vassiliadis
发明人： Sanne S. Veidal , Morten A. Karsdal , Diana J. Leeming , Natasha Barascuk , Helene Skjøt-Arkil , Efstathios Vassiliadis
IPC分类号： G01N31/00 , G01N33/53 , G01N33/68 , C07K14/78 , C12Q1/37
CPC分类号： G01N33/6893 , C07K14/78 , C12Q1/37 , G01N2333/4737 , G01N2333/775 , G01N2333/78 , G01N2800/32
摘要： Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described.
摘要翻译：诊断或定量的病理状况的方法包括进行免疫测定以测量天然存在于生物流体样品中的含有蛋白质片段的蛋白质片段，并将患者的标准物高于常规水平与病理学的存在或程度相关联。通过以下方法进行免疫测定：将天然存在于样品中的蛋白质片段与免疫结合配偶体接触，所述免疫结合配偶体与通过蛋白酶切割蛋白质形成的新表位反应，并测量肽片段与免疫结合的程度在其中测量包含新表位的蛋白质片段的伴侣。描述了I型胶原，III型胶原，IV型胶原，V型胶原蛋白，弹性蛋白，双聚糖，核心蛋白聚糖，多巴胺，多巴胺，C反应蛋白，ApoE和层粘连蛋白的新表位。

78. 发明授权

US09372197B2 Flourescent in-situ detection of lipid particle apolipoproteins within primary electrophoretic matrix 有权
标题翻译：荧光原位检测初级电泳基质中的脂质颗粒载脂蛋白
公开(公告)号：US09372197B2
公开(公告)日：2016-06-21
申请号：US14194142
申请日：2014-02-28
申请人： Health Diagnostic Laboratory, Inc.
发明人： Philip Guadagno , Erin Grace Bellin
IPC分类号： G01N33/53 , G01N31/00 , G01N33/92 , G01N33/561
CPC分类号： G01N33/92 , G01N21/6428 , G01N27/44726 , G01N27/44747 , G01N27/44756 , G01N33/561 , G01N2021/6441 , G01N2333/775 , G01N2550/00 , G01N2800/32 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to, among other things, a gel electrophoresis system for detecting the level of specific Apolipoproteins and/or lipoprotein particles present in intact lipid particles in a biological sample. The system includes a gel substrate to receive a biological sample, at least two lipoprotein-binding complexes. Each complex includes an antibody that binds a lipoprotein particle or a portion thereof, which is bound to a signal producing molecule capable of producing or causing production of a detectable signal. The system also includes a device for detecting the detectable signal. The present invention also relates to methods of assessing the level of specific Apolipoproteins and/or lipoprotein particles present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease, and monitoring the risk for developing cardiovascular disease.
摘要翻译：本发明尤其涉及用于检测存在于生物样品中完整脂质颗粒中的特定载脂蛋白和/或脂蛋白颗粒的水平的凝胶电泳系统。该系统包括用于接收生物样品的凝胶底物，至少两种脂蛋白结合复合物。每个复合物包括结合脂蛋白颗粒或其部分的抗体，其结合于能够产生或引起产生可检测信号的信号产生分子。该系统还包括用于检测可检测信号的装置。本发明还涉及评估生物样品中存在的特定载脂蛋白和/或脂蛋白颗粒的水平的方法，确定受试者是否处于心血管疾病风险增加以及监测发展心血管疾病的风险。

79. 发明申请

US20160146818A1 BLADDER CANCER DETECTION COMPOSITION, KIT, AND ASSOCIATED METHODS 审中-公开
标题翻译：刀片检测组合物，套件及相关方法
公开(公告)号：US20160146818A1
公开(公告)日：2016-05-26
申请号：US15011584
申请日：2016-01-31
申请人： Steven GOODISON , Charles J. ROSSER
发明人： Steven GOODISON , Charles J. ROSSER
IPC分类号： G01N33/574 , G06F19/18
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/158 , G01N33/6893 , G01N2333/5421 , G01N2333/775 , G01N2333/8132 , G01N2333/916 , G01N2333/96494 , G01N2800/52 , G01N2800/7028 , G06F19/18
摘要： Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of bladder cancer in a subject are provided by detecting in a urine sample a combination of biomarkers. In one embodiment of the invention, biomarker panels consisting of individual targets listed in Tables 4 through 10 may be detected. In another embodiment of the invention, multiplex biomarker panels of various composition, but including those biomarkers listed above may be detected.
摘要翻译：通过在尿样中检测生物标志物的组合来提供对象中膀胱癌的诊断，预后和监测的组合物，试剂盒和方法。在本发明的一个实施方案中，可以检测由表4至10中列出的各个靶组成的生物标志物面板。在本发明的另一个实施方案中，可以检测到各种组成的复合生物标志物组，但包括上述那些生物标志物。

80. 发明申请

US20160139160A1 CARDIOVASCULAR DISEASE RISK ASSESSMENT 有权
标题翻译：心血管疾病风险评估
公开(公告)号：US20160139160A1
公开(公告)日：2016-05-19
申请号：US14943775
申请日：2015-11-17
申请人： Boston Heart Diagnostic Corporation
发明人： Ernst J. Schaefer
IPC分类号： G01N33/92 , G06F19/12 , G06F19/24
CPC分类号： G01N33/92 , G01N2333/775 , G01N2405/00 , G01N2800/32 , G01N2800/50 , G06F19/24
摘要： The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers LDL and HDL subfractions, along with Lp(a) provides significant improvement in predicting CVD versus standard assays that include standard risk factors. Methods of the invention comprise measuring LDL and HDL subfractions in addition to Lp(a) without reference to standard risk factor measurements, such as CRP, total cholesterol, body mass index, weight, triglycerides, and the like. It is unexpected that an algorithm focusing only on LDL and HDL subfractions and Lp(a) would be more informative as to CVD risk than measurements that are much more comprehensive in terms of the markers that are reviewed. In particular, the sdLDL-C subfraction of LDL and the ApoA-1 in large alpha-1 HDL are most informative in conjunction with Lp(a).
摘要翻译：本发明提供了用于分析心血管疾病风险的改进方法。根据本发明，考虑LDL和HDL亚组分以及Lp（a）的算法在预测CVD与包括标准危险因素的标准测定相比提供了显着的改进。本发明的方法包括除了Lp（a）之外还测量LDL和HDL亚组分，而不参考诸如CRP，总胆固醇，体重指数，体重，甘油三酸酯等的标准危险因素测量。令人意想的是，仅针对LDL和HDL亚分数和Lp（a）的算法对于CVD风险来说将比对所审查标记方面更为全面的测量更具信息。特别地，LDL和ApoA-1在大α-1 HDL中的sdLDL-C亚分类与Lp（a）结合是最有说服力的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式